[go: up one dir, main page]

WO2011027060A3 - Traitement par l'ocytocine de caracteristiques comportementales associees a l'autisme et a la timidite pathologique - Google Patents

Traitement par l'ocytocine de caracteristiques comportementales associees a l'autisme et a la timidite pathologique Download PDF

Info

Publication number
WO2011027060A3
WO2011027060A3 PCT/FR2010/051660 FR2010051660W WO2011027060A3 WO 2011027060 A3 WO2011027060 A3 WO 2011027060A3 FR 2010051660 W FR2010051660 W FR 2010051660W WO 2011027060 A3 WO2011027060 A3 WO 2011027060A3
Authority
WO
WIPO (PCT)
Prior art keywords
autism
shyness
disorder
characteristics associated
behavioral characteristics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2010/051660
Other languages
English (en)
Other versions
WO2011027060A2 (fr
Inventor
Angela Sirigu
Elissar Andari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Claude Bernard Lyon 1
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Claude Bernard Lyon 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Claude Bernard Lyon 1 filed Critical Centre National de la Recherche Scientifique CNRS
Publication of WO2011027060A2 publication Critical patent/WO2011027060A2/fr
Publication of WO2011027060A3 publication Critical patent/WO2011027060A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention se rapporte à l'utilisation de l'ocytocine ou d'un analogue de celle-ci pour la prévention ou le traitement d'une ou plusieurs caractéristiques comportementales associées aux troubles du spectre autistique (ou autisme) et à la timidité pathologique.
PCT/FR2010/051660 2009-09-04 2010-08-05 Traitement par l'ocytocine de caracteristiques comportementales associees a l'autisme et a la timidite pathologique Ceased WO2011027060A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09290674.2 2009-09-04
EP09290674 2009-09-04
EP09290824 2009-10-28
EP09290824.3 2009-10-28

Publications (2)

Publication Number Publication Date
WO2011027060A2 WO2011027060A2 (fr) 2011-03-10
WO2011027060A3 true WO2011027060A3 (fr) 2011-04-28

Family

ID=43066863

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2010/051660 Ceased WO2011027060A2 (fr) 2009-09-04 2010-08-05 Traitement par l'ocytocine de caracteristiques comportementales associees a l'autisme et a la timidite pathologique

Country Status (2)

Country Link
FR (1) FR2954167A1 (fr)
WO (1) WO2011027060A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
CN113993522A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗焦虑障碍、头痛病症和进食障碍的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004030524A2 (fr) * 2002-10-03 2004-04-15 Pr Pharmaceuticals Traitement de l'autisme et de troubles similaires
WO2008042452A1 (fr) * 2006-09-29 2008-04-10 Nastech Pharmaceutical Company Inc. Compositions pharmaceutiques comprenant de l'ocytocine ou un analogue pour le traitement de l'autisme
WO2008150305A1 (fr) * 2007-06-07 2008-12-11 Nastech Pharmaceutical Company Inc. Formulation de carbétocine intranasale et procédés de traitement de l'autisme

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9701161D0 (sv) 1997-03-27 1997-03-27 Karolinska Innovations Ab New use I
SE0102184D0 (sv) 2001-06-19 2001-06-19 Uvnaes Moberg Kerstin New subject-matter
KR20080063848A (ko) 2005-10-24 2008-07-07 와이어쓰 옥시토신 수용체 작용제로 유용한 트리사이클릭 화합물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004030524A2 (fr) * 2002-10-03 2004-04-15 Pr Pharmaceuticals Traitement de l'autisme et de troubles similaires
WO2008042452A1 (fr) * 2006-09-29 2008-04-10 Nastech Pharmaceutical Company Inc. Compositions pharmaceutiques comprenant de l'ocytocine ou un analogue pour le traitement de l'autisme
WO2008150305A1 (fr) * 2007-06-07 2008-12-11 Nastech Pharmaceutical Company Inc. Formulation de carbétocine intranasale et procédés de traitement de l'autisme

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Thursday Abstracts", BIOLOGICAL PSYCHIATRY, vol. 63, no. 7, 13 March 2008 (2008-03-13), ELSEVIER SCIENCE, NEW YORK, NY, US, pages 1S - 111S, XP022518192, ISSN: 0006-3223, DOI: 10.1016/J.BIOPSYCH.2008.02.010 *
COSTA P T JR ET AL: "Overview: innovations in assessment using the revised NEO personality inventory", ASSESSMENT, PAR, PSYCHOLOGICAL ASSESMENT RESOURCES, US, vol. 7, no. 4, 1 December 2000 (2000-12-01), pages 325 - 327, XP009143969, ISSN: 1073-1911 *
GUASTELLA ET AL: "Oxytocin Increases Gaze to the Eye Region of Human Faces", BIOLOGICAL PSYCHIATRY, vol. 63, no. 1, 12 December 2007 (2007-12-12), ELSEVIER SCIENCE, NEW YORK, NY, US, pages 3 - 5, XP022387459, ISSN: 0006-3223, DOI: 10.1016/J.BIOPSYCH.2007.06.026 *
HOLLANDER ET AL: "Oxytocin Increases Retention of Social Cognition in Autism", BIOLOGICAL PSYCHIATRY, vol. 61, no. 4, 2 February 2007 (2007-02-02), ELSEVIER SCIENCE, NEW YORK, NY, US, pages 498 - 503, XP005871294, ISSN: 0006-3223, DOI: 10.1016/J.BIOPSYCH.2006.05.030 *
THOMPSON R ET AL: "The effects of vasopressin on human facial responses related to social communication.", PSYCHONEUROENDOCRINOLOGY, vol. 29, no. 1, January 2004 (2004-01-01), pages 35 - 48, XP002619872, ISSN: 0306-4530 *

Also Published As

Publication number Publication date
FR2954167A1 (fr) 2011-06-24
WO2011027060A2 (fr) 2011-03-10

Similar Documents

Publication Publication Date Title
WO2011133875A3 (fr) Composés inhibiteurs de métalloenzyme
WO2012177603A3 (fr) Composés inhibiteurs de métalloenzymes
IN2014DN00288A (fr)
IN2014DN00286A (fr)
WO2011140202A3 (fr) Modulateurs de mif
WO2011091366A3 (fr) Procédés de traitement ou de prévention de la parodontite et maladies associées à la parodontite
EP4324527A3 (fr) Formulations d'enzalutamide
HK1223093A1 (zh) 杀真菌组合物
IN2014MN01378A (fr)
WO2011082245A3 (fr) Composés inhibiteurs de métallo-enzyme
WO2011141823A3 (fr) Méthodes de traitement et/ou de prévention de troubles de prolifération cellulaire à l'aide d'antagonistes de il-17
IN2014DN06792A (fr)
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
IN2012DN00624A (fr)
WO2014055996A3 (fr) Inhibiteurs de rho kinase
WO2011090738A3 (fr) Inhibiteurs de kinase raf de type ii
WO2014015210A3 (fr) Micro-organismes et procédés de conversion de glycérol en isoprène
WO2011129936A3 (fr) Compositions et procédés pour la prévention et le traitement du cancer
EP2765227A3 (fr) Compositions et procédés permettant d'identifier des troubles du spectre autistique
EP3041577A4 (fr) Traitement et prévention de l'autisme et des troubles du spectre autistique
WO2011150457A3 (fr) Inhibiteurs de la prostaglandine d2 synthase hématopoïétique
WO2012058529A3 (fr) Composés inhibiteurs de métalloenzymes
WO2009136997A3 (fr) Inhibiteurs des cathepsines l, b et s humaines
GB2455585B (en) Capsicum seeds for the treatment of eczema and dermatitis
WO2012082746A3 (fr) Composés inhibiteurs de métalloenzyme

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10762971

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10762971

Country of ref document: EP

Kind code of ref document: A2